Organisation paid for research Program year 2025 Source: CMS Open Payments

Central States Research

Neither a doctor nor a teaching hospital

Research payments

$674,790

40 payments

Through program year 2025, Central States Research is reported as receiving $674,790 in research payments, across 40 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $21,156 5
2024 Research $6,000 1
2023 Research $647,634 34

Breakdown

Who paid Research payments · program years 2023–2025
  1. Eisai Inc. $647,135 33 payments
  2. Pfizer Inc. $18,456 4 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $8,700 2 payments
  4. AbbVie, Inc. $499 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $647,135 33 payments
  2. A Phase 1 Multicenter Openlabel Singledose Study to Evaluate the Safety Tolerability and Pharmacokinetics of Zavegepant in Children 6 to Less Than 12 Years of Age With History of Migraine $18,456 4 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $6,000 1 payment
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $2,700 1 payment
  5. A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimers Disease $499 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record